Although ESAs may improve quality of life, many studies in dialysis-dependent CKD patients have found that when the protocol goal is to achieve higher hemoglobin (Hb) levels, the mortality rate is higher when using high doses of ESAs [6]. Here, GSTM1 is linked to chronic kidney disease.